Direkt zum Inhalt
Merck
Alle Fotos(1)

Key Documents

Y0000481

Dibrompropamidin für die Systemeignung

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

Dibrompropamidin-diisetionat

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C21H30Br2N4O10S2
CAS-Nummer:
614-87-9
Molekulargewicht:
722.42
UNSPSC-Code:
41116107
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

dibrompropamidine

Hersteller/Markenname

EDQM

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

InChI

1S/C17H18Br2N4O2.C2H6O4S/c18-12-8-10(16(20)21)2-4-14(12)24-6-1-7-25-15-5-3-11(17(22)23)9-13(15)19;3-1-2-7(4,5)6/h2-5,8-9H,1,6-7H2,(H3,20,21)(H3,22,23);3H,1-2H2,(H,4,5,6)

InChIKey

BZACJASHKPPTKX-UHFFFAOYSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Dibrompropamidine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Verpackung

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Leider sind derzeit keine COAs für dieses Produkt online verfügbar.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

M T Suller et al.
The Journal of hospital infection, 43(4), 281-291 (2000-02-05)
Concern has been growing regarding the potential of antibiotic and disinfectant co-resistance in clinically important bacteria. In this study, the susceptibilities of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (MSSA) to chlorhexidine (CHX), the quaternary ammonium compounds cetylpyridinium chloride
Victoria W Y Wong et al.
Eye & contact lens, 33(6 Pt 1), 329-331 (2007-11-13)
To describe a patient with a good visual outcome after prompt treatment of Acanthamoeba keratitis as a complication of overnight orthokeratology lens wear. Interventional case report. A 9-year-old boy experienced pain, photophobia, and redness in his right eye 3 days
R Yeoh et al.
The British journal of ophthalmology, 71(7), 500-503 (1987-07-01)
We report on four patients seen during the past two years who had acanthamoeba keratitis. One is described in detail. We believe that acanthamoebic eye infection is not rare. An immunofluorescent technique for localisation of amoebae and cysts is described.
L A Shaker et al.
The Journal of applied bacteriology, 64(6), 531-539 (1988-06-01)
Chlorhexidine diacetate (CHA) was rather more sporicidal at 20 degrees C to urea-dithreitol-sodium lauryl sulphate (UDS)-treated spores of Bacillus subtilis NCTC 8236 than to urea-dithiothreitol (UDT)-treated or normal (untreated) spores. UDS spores adsorbed more CHA from solution than did the
Contact allergy to dibrompropamidine cream.
S Wright
Contact dermatitis, 9(3), 226-226 (1983-05-01)
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.